- GlobeNewswire•7 hours ago
SOUTH SAN FRANCISCO, Calif., March 29, 2017-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16 th Annual ...
- GlobeNewswire•16 hours ago
Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
Data Monitoring Committee Agrees to Proceed to Higher Dose Cohort. One of Four Clinical Trials in 2017 under Astellas Collaboration. SOUTH SAN FRANCISCO, Calif., March 29, 2017-- Cytokinetics, Inc. today ...
- GlobeNewswire•7 days ago
Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS
AND SOUTH SAN FRANCISCO, Calif., March 23, 2017-- Origent Data Sciences, Inc. and Cytokinetics, Inc. today announced the advancement of their research collaboration to prospectively validate Origent’ s ...
CYTK : Summary for Cytokinetics, Incorporated - Yahoo Finance
Cytokinetics, Incorporated (CYTK)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||11.05 x 400|
|Day's Range||12.43 - 12.70|
|52 Week Range||6.54 - 13.70|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|